MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

MAKE WAY FOR THE FIRST ACTIVE HEMOSTATIC POWDER

Working together to improve surgery for both patients and surgeons

OUR VISION

Working in partnership with surgeons, we create, develop, and distribute innovative surgical products. At Biom’up, we are dedicated to optimizing surgery with a double objective: to boost surgeons performances and improve patients well-being.

OUR KNOW-HOW

HEMOBLAST™ Bellows is the result of more than a decade of expertise in the design, development, and delivery of collagen-based high-performing solutions for surgery.

We are developing a new generation of hemostatic products for use in a wide range of surgical specialties, including orthopedics, spine, cardiothoracic, general, maxillofacial ,and dental surgery.

Biom’up has already created several collagen-based products (COVA™, MATRI™ BONE), that have paved the way for the development and the success of HEMOBLAST™ Bellows.

2019
2018

1st trimester

  • Announcement of the construction of a new production plant
  • €16 million capital increase

2d trimester

  • 200 surgeons and KOL trained in the US
  • Bond financing for €25 million with Athyrium
  • Finalization of commercial organization in the US

3rd trimester

  • CE Mark for HEMOBLAST™ Bellows Laparoscopic Applicator
  • First sales of HEMOBLAST™ Bellows in the US

4th trimester

  • Filing of a reimbursement dossier for HEMOBLAST™ Bellows in Australia
  • Completion of the scale-up of manufacturing facility
  • 6 key manufacturing processes upgraded and approved by FDA and EMA
  • Exclusive distribution agreement in Spain
  • €7,67 million capital increase
  • €3 million raised bringing bond financing with Athyrium up to €28 million
2017
  • Biom’up receives FDA marketing approval for
    HEMOBLAST™ Bellows
  • Completion of the pivotal clinical study assessing HEMOBLAST™ Bellows in the U.S.A.
  • European launch
  • Biom’up launches its IPO on the Euronext regulated market in Paris and raise 38,1 M€
2016
  • CE marking of HEMOBLAST™ Bellows
  • Conducting pilot study (27 patients)
  • The IDE authorizes the launch of a pivotal clinical study of HEMOBLAST™ Bellows in humans
  • Inclusion of the first patient in the pivotal clinical study, prospective, randomized, multicentric clinical trial assessing the efficacy and safety of HEMOBLAST™ Bellows in most types of surgery
  • Over 150 000 medical devices implanted in Europe
2014

Biom’up opens two subsidiaries in the USA and in Germany

2013
  • CE marking and launch of the COVAMESH™ range
  • Second FDA 510(k) clearance, for the COVAMESH™ range
  • Certified to ISO 13485 and ISO 9001 by the SNCH and by the BSI
2012
  • CE marking and launch of the HEMOSNOW™ range
  • Second FDA 510(k) clearance, for the COVA™ ORTHO NERVE
  • Over 100 000 medical devices implanted in Europe
  • Raised 6,8 M€
2011

First FDA 510(k) clearance, for the COVA™ MAX range

2010

Raised 3 M€

2009

CE marking and launch of the COVA™ and MATRI™ ranges

2008

Raised 1,5 M€

2007

Approval and development of the first OEM products

2006

ISO 9001 and ISO 13485 certifications

2005

Creation of 

Visit Biom'up website

Find out more about HEMOBLAST™ Bellows

Legal Information: HEMOBLAST™ Bellows - Implantable Medical device Class III for surgery reserved for use by qualified healthcare professionals, reimbursement depends on each country.
Read the instructions for use on the packaging carefully before use. CE0086: BSI - Manufacturer: Biom’up SA France.